Literature DB >> 3086106

Alfentanil kinetics in renal insufficiency.

A Van Peer, M Vercauteren, H Noorduin, R Woestenborghs, J Heykants.   

Abstract

Alfentanil 100 micrograms/kg was administered as an i.v. bolus to 9 patients with severe chronic renal dysfunction (creatinine clearance 1.0 +/- 1.2 ml/min) requiring regular haemodialysis. Plasma alfentanil concentrations were measured by a specific radioimmunoassay. Individual plasma concentration-time curves were fitted to a two-compartment open model. Mean distribution and elimination half-lives were 3.7 min and 58 min, respectively. The apparent volumes of distribution of the central compartment and the total volume of distribution at steady-state were 91 ml/kg and 304 ml/kg, respectively. Alfentanil plasma clearance was 5.3 +/- 2.5 ml/min/kg. All the patients tolerated alfentanil well and no side-effects nor delayed recovery were observed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3086106     DOI: 10.1007/bf00614313

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  5 in total

1.  Plasma protein binding and distribution of fentanyl, sufentanil, alfentanil and lofentanil in blood.

Authors:  W E Meuldermans; R M Hurkmans; J J Heykants
Journal:  Arch Int Pharmacodyn Ther       Date:  1982-05

2.  Serum alpha-1-acid glycoprotein (orosomucoid) in uremic patients on hemodialysis.

Authors:  H J Henriksen; M U Petersen; F B Pedersen
Journal:  Nephron       Date:  1982       Impact factor: 2.847

3.  [Clinical pharmacokinetics of alfentanyl (author's transl)].

Authors:  J Schüttler; H Stoeckel
Journal:  Anaesthesist       Date:  1982-01       Impact factor: 1.041

4.  Alfentanil kinetics in the elderly.

Authors:  H Helmers; A Van Peer; R Woestenborghs; H Noorduin; J Heykants
Journal:  Clin Pharmacol Ther       Date:  1984-08       Impact factor: 6.875

5.  Radioimmunoassay of the new opiate analgesics alfentanil and sufentanil. Preliminary pharmacokinetic profile in man.

Authors:  M Michiels; R Hendriks; J Heykants
Journal:  J Pharm Pharmacol       Date:  1983-02       Impact factor: 3.765

  5 in total
  7 in total

Review 1.  Sedation for fibreoptic bronchoscopy.

Authors:  M P Shelley; P Wilson; J Norman
Journal:  Thorax       Date:  1989-10       Impact factor: 9.139

Review 2.  The role of opioids in cancer pain.

Authors:  Columba Quigley
Journal:  BMJ       Date:  2005-10-08

3.  Aging and alfentanil disposition in healthy volunteers and surgical patients.

Authors:  D S Sitar; P C Duke; J L Benthuysen; T J Sanford; N T Smith
Journal:  Can J Anaesth       Date:  1989-03       Impact factor: 5.063

Review 4.  Clinical pharmacokinetics of alfentanil, fentanyl and sufentanil. An update.

Authors:  J Scholz; M Steinfath; M Schulz
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

Review 5.  Pharmacokinetics and pharmacodynamics of sedatives and analgesics in the treatment of agitated critically ill patients.

Authors:  B K Wagner; D A O'Hara
Journal:  Clin Pharmacokinet       Date:  1997-12       Impact factor: 6.447

Review 6.  The altered pharmacokinetics and pharmacodynamics of drugs commonly used in critically ill patients.

Authors:  A Bodenham; M P Shelly; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-06       Impact factor: 6.447

Review 7.  Alfentanil infusions in patients requiring intensive care.

Authors:  A Bodenham; G R Park
Journal:  Clin Pharmacokinet       Date:  1988-10       Impact factor: 6.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.